Lv3
400 积分 2022-05-11 加入
Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models
1个月前
已完结
The Biosimilar Paradox
2个月前
已完结
Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration
2个月前
已完结
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
2个月前
已完结
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial
2个月前
已完结
Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology
2个月前
已关闭
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
2个月前
已完结
Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management
2个月前
已完结
Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story
3个月前
已完结
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
3个月前
已完结
皖公网安备34019202002308
